By Cormac Sheridan Staff Writer DUBLIN, Ireland – Elan Corp

It would be a stretch for us to do two of them a year," Spork said.

It would be a stretch for us to do two of them a year," Spork said.

If they don't deliver on that potential, Elan's shareholders will have an expensive jigsaw puzzle on their hands.

If they don't deliver on that potential, Elan's shareholders will have an expensive jigsaw puzzle on their hands.

and Cytori Therapeutics Inc., of San Diego.

He still holds more than 40 percent of its stock.

Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307 for details.

He still holds more than 40 percent of its stock.

Editor's note: To obtain a CD of the webinar, "Royalty Financing for Biotech and Medical Device Companies: How to Determine Eligibility and Take Advantage of this Unique Financing Opportunity" or for a deeper dive, BioWorld's Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking, call 800-477-6307 for details.

and Cytori Therapeutics Inc., of San Diego.

The General Court of the European Union recently ordered the EMA not to release data pending the final judgement in the main cases the two companies have brought.

OPN-305 now takes its place alongside MGN1703 as one of the industry's most closely watched TLR-targeted programs.

It also has secured access to the technology platforms of Seattle Genetics Inc., of Bothell, Wash., and BioWa Inc., of Princeton, N.J.

Rainer Strohmenger, general partner at Munich, Germany-based Wellington, has joined Genticel's board.

It also has secured access to the technology platforms of Seattle Genetics Inc., of Bothell, Wash., and BioWa Inc., of Princeton, N.J.

Roth Capital Partners acted as sole manager for the offering.

Rainer Strohmenger, general partner at Munich, Germany-based Wellington, has joined Genticel's board.

J&J offered some 92 percent of the 88.9 million shares tendered (at $11.25 per share), and it has reduced its stake from 18.4 percent to less than 5 percent.